Carolina Victor

Dr. Carolina Victor

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Verified
Journal Article
Open access
PDF file
SHStefany Hong
Stefany Hong
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
Carolina VictorCarolina Victor
Carolina Victor
JGJoão Vitor Antunes Gregório
João Vitor Antunes Gregório
BZBruno Zilberstein
Bruno Zilberstein
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
BACKGROUND: Surgical resection remains the main curative therapeutic modality for advanced gastric cancer. Recently, the association of preoperative chemotherapy has allowed the improvement of results without increasing surgical complications. AIMS: To evaluate the surgical and oncological outcomes of preoperative chemotherapy in a real-world setting. METHODS: A retrospective review of gastric cancer patients who underwent gastrectomy was performed. Patients were divided into two groups for analysis: upfront surgery and preoperative chemotherapy. The propensity score matching analysis, including 9 variables, was applied to adjust for potential confounding factors. RESULTS: Of the 536 patients included, 112 (20.9%) were referred for preoperative chemotherapy. Before the propensity score matching analysis, the groups were different in terms of age, hemoglobin level, node metastasis at clinical stage- status, and extent of gastrectomy. After the analysis, 112 patients were stratified for each group. Both were similar for all variables assigned in the score. Patients in the preoperative chemotherapy group had less advanced postoperative p staging (p=0.010), postoperative n staging (p<0.001), and pTNM stage (p<0.001). Postoperative complications, 30- and 90-days mortality were similar between both groups. Before the propensity score matching analysis, there was no difference in survival between the groups. After the analysis, patients in the preoperative chemotherapy group had better overall survival compared to upfront surgery group (p=0.012). Multivariate analyses demonstrated that American Society of Anesthesiologists III/IV category and the presence of lymph node metastasis were factors significantly associated with worse overall survival. CONCLUSIONS: Preoperative chemotherapy was associated with increased survival in gastric cancer. There was no difference in the postoperative complication rate and mortality compared to upfront surgery.

1 January 2023 in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Verified
Journal Article
Open access
PDF file
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
ACAmir Zeide Charruf
Amir Zeide Charruf
Carolina VictorCarolina Victor
Carolina Victor
JGJoão Vitor Antunes Marques Gregorio
João Vitor Antunes Marques Gregorio
ADAndre Roncon Dias
Andre Roncon Dias
BACKGROUND: Peritoneal carcinomatosis in gastric cancer is considered a fatal disease, without expectation of definitive cure. As systemic chemotherapy is not sufficient to contain the disease, a multimodal approach associating intraperitoneal chemotherapy with surgery may represent an alternative for these cases. AIMS: The aim of this study was to investigate the role of intraperitoneal chemotherapy in stage IV gastric cancer patients with peritoneal metastasis. METHODS: This study is a single institutional single-arm prospective clinical trial phase II (NCT05541146). Patients with the following inclusion criteria undergo implantation of a peritoneal catheter for intraperitoneal chemotherapy: Stage IV gastric adenocarcinoma; age 18–75 years; Peritoneal carcinomatosis with peritoneal cancer index<12; Eastern Cooperative Oncology Group 0/1; good clinical status; and lab exams within normal limits. The study protocol consists of four cycles of intraperitoneal chemotherapy with paclitaxel associated with systemic chemotherapy. After treatment, patients with peritoneal response assessed by staging laparoscopy undergo conversion gastrectomy. RESULTS: The primary outcome is the rate of complete peritoneal response. Progression-free and overall survivals are other outcomes evaluated. The study started in July 2022, and patients will be screened for inclusion until 30 are enrolled. CONCLUSIONS: Therapies for advanced gastric cancer patients have been evaluated in clinical trials but without success in patients with peritoneal metastasis. The treatment proposed in this trial can be promising, with easy catheter implantation and ambulatory intraperitoneal chemotherapy regime. Verifying the efficacy and safety of paclitaxel with systemic chemotherapy is an important progress that this study intends to investigate.

21 November 2025 in Clinics
Verified
Journal Article
Open access
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
ADAndre Roncon Dias
Andre Roncon Dias
OYOsmar Kenji Yagi
Osmar Kenji Yagi
BNBruna de Camargo Nigro
Bruna de Camargo Nigro
URUlysses Ribeiro-Junior
Ulysses Ribeiro-Junior
The treatment of Gastric Cancer (GC) has evolved with advances in multimodal therapy and minimally invasive surgery. This study aimed to provide an overview of the current treatment and survival outcomes of GC at a public high-volume cancer center during 15 years. Patients with gastric adenocarcinoma who underwent any surgical procedure between January 2009 and December 2023 were retrospectively included. To investigate temporal differences in patient characteristics and therapeutic approaches, the case cohort was divided into two time periods: Period I (2009-2016) and II (2016-2023). A total of 1406 patients were included: 741 (52.7 %) were treated in Period I, and 665 (47.3 %) in Period II. The proportion of curative-intent surgeries remained stable (65.2% vs. 65.1), but diagnostic procedures increased (7.3 % vs. 12.2). Overall, 804 (57.2 %) patients underwent potentially curative gastrectomy. In Period II, patients had advanced ASA scores, more advanced clinical staging, and more frequent D1 lymphadenectomy (all p < 0.05). The use of minimally invasive surgery and the number of resected lymph nodes increased (both p < 0.001). Multimodal treatment became more frequent, with increased use of preoperative chemotherapy (p = 0.03). There were no significant differences in postoperative complications or 30- and 90-day mortality rates between the two periods. In multivariable analysis, advanced age, ASA III/IV, total gastrectomy, D1 lymphadenectomy, diffuse/mixed histology, advanced pT stage, and lymph node metastasis were independent factors associated with worse survival (all p < 0.05). Over 15 years, treatment evolved toward increased use of minimally invasive and multimodal approaches, with no impact on short-term surgical outcomes.

21 August 2025 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
RMRaelson Rodrigues Miranda
Raelson Rodrigues Miranda
ERErika Andrade Rocha
Erika Andrade Rocha
ARAmanda Acioli de Almeida Robatto
Amanda Acioli de Almeida Robatto
DGDenis Artico Galhera
Denis Artico Galhera
Carolina VictorCarolina Victor
Carolina Victor
CMCamila Motta Venchiarutti Moniz
Camila Motta Venchiarutti Moniz
Background: Although anal cancer is a rare malignancy, its incidence is up to 30 times higher among individuals living with HIV. Recent evidence suggests that Highly Active Antiretroviral Therapy (HAART) regimens containing sulfonyl groups may exhibit antitumor properties. Based on these findings, we hypothesize that HAART regimens incorporating sulfonyl-containing compounds could influence oncologic outcomes in HIV-positive patients undergoing definitive chemoradiotherapy (CRT) for anal cancer. Methods: From a cohort of 537 patients with stage I–III invasive anal cancer treated between August 2010 and April 2022, 56 HIV-positive patients who underwent definitive chemoradiotherapy were included in the analysis. . Results: Most patients were male. The mean age was 52 years in the non-sulfonyl-HAART group and 53 years in the sulfonyl-HAART group. The mean CD4 count was significantly higher in the non-sulfonyl group compared to the sulfonyl group (523 vs. 287 cells/mm³, p = 0.02). Grade 3–4 toxicities occurred in 60% and 38% of patients, respectively (p = 0.18). Chemotherapy dose reductions were required in 10% of the non-sulfonyl group and 8% of the sulfonyl group (p = 1.0). Treatment discontinuation during chemoradiotherapy occurred in 17% vs. 23% of patients, respectively (p = 0.7). The overall response rate at 6 months post-treatment was significantly higher in the sulfonyl-HAART group (100%) compared to the non-sulfonyl group (20/36; 55.6%), Odds Ratio (OR) 0.00, 95% CI: 0–0.72, p = 0.004). After adjustment, CD4 count was not associated with treatment response (logistic regression OR: 1.00; 95% CI: 0.99– 1.00, p = 0.3). The median progression-free survival (PFS) in the non-sulfonyl-HAART group was 70 months (p = 0.45), and overall survival (OS) was similar between groups (p = 0.6); the median OS was not reached in the sulfonyl-HAART group. In the Cox proportional hazards model, age, clinical stage, and lack of response to CRT at 6 months were independent predictors of worse survival. ( Conclusion: HIV-positive patients with anal cancer who received sulfonyl-containing HAART during definitive chemoradiotherapy demonstrated a significantly higher overall response rate at 6 months, independent of baseline CD4 count. However, no significant differences were observed between the sulfonyl and non-sulfonyl groups in terms of treatment-related toxicities, treatment discontinuation, progression-free survival, or overall survival.

14 July 2026 in Clinics
Verified
Journal Article
Open access
CMCamila M.VEnchiarutti Moniz
Camila M.VEnchiarutti Moniz
RBRenata Colombo Bonadio
Renata Colombo Bonadio
FLFelippe Lazar
Felippe Lazar
ACAndre Chen
Andre Chen
RRRenan Ribeiro e Ribeiro
Renan Ribeiro e Ribeiro
PHPaulo M. Hoff
Paulo M. Hoff
Circulating tumor DNA (ctDNA) is a promising biomarker to predict recurrence in solid tumors such as colorectal and breast cancer. Defining complete response after chemoradiation remains challenging, as post-treatment inflammatory and tissue changes limit clinical and imaging evaluation. The authors conducted a prospective longitudinal study of patients with localized cervical and anal cancer treated with curative-intent chemoradiation with the aim of evaluating the role of ctDNA as a predictor of recurrence. Blood specimens were collected at D1, D29, immediately post-treatment, 8-weeks, 24-weeks, and every 6-months up to 5-years. ctDNA testing (Signatera™) was provided by Natera as an in-kind donation. The primary endpoint was correlation between 8-week ctDNA and recurrence. 28 patients were evaluable. Ten recurrences occurred, all in patients with positive ctDNA after chemoradiation and before radiologic progression. The median interval between ctDNA positivity and radiologic progression was 3.0-months (range 0.5-21.3). All patients with radiologic complete response at 6 months had negative 8-week ctDNA. Among those without complete response, 8-week ctDNA identified most who later progressed (6/8), while all without complete response who did not progress had negative ctDNA. Eight-week ctDNA positivity was strongly associated with inferior progression-free survival: median 6.7-months in ctDNA-positive versus not reached in ctDNA-negative patients (HR = 40.09, p = 0.001). Among patients with cervical and anal cancer, ctDNA monitoring after definitive chemoradiation identifies individuals without complete response and predicts recurrence. ctDNA positivity at 8-weeks identifies a very high-risk group for whom treatment intensification trials are warranted.